Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
March 09 2023 - 6:00AM
Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage
biotechnology company developing a novel platform of orally
delivered inflammation-resolving medicines acting on the small
intestinal axis, SINTAX, today announced that it will host a
conference call and live webcast at 8:30 a.m. ET on Thursday, March
16, 2023 to report its fourth quarter and full year 2022 financial
results and business highlights.
To listen to the conference call by phone, participants must
pre-register here. A live webcast can be accessed under "News &
Events" in the investors section of Evelo’s website,
https://ir.evelobio.com/news-events. The archived webcast will be
available on Evelo’s website for approximately 30 days following
the event.
About Evelo BiosciencesEvelo Biosciences is a
clinical stage biotechnology company developing a novel platform of
orally delivered anti-inflammatory medicines acting on the small
intestinal axis, SINTAX, with systemic therapeutic effects. The
small intestine plays a central role in governing inflammation
throughout the body. The Company’s product candidates are
pharmaceutical preparations of single strains of microbes or their
extracellular vesicles (EVs). Evelo initially is developing EDP1815
in psoriasis and atopic dermatitis and EDP2939 in psoriasis.
Evelo’s vision is to create therapies that are effective, safe,
well-tolerated, and affordable to improve the lives of the billions
of people living with inflammatory diseases. If shown to be
effective in inflammatory disease mediated by the Th1, Th2 or Th17
inflammatory pathways, these same investigational medicines could
be effective in additional inflammatory diseases, such as psoriatic
and other forms of arthritis, asthma, allergy, and inflammatory
bowel disease.
For more information, please
visit www.evelobio.com and engage with Evelo
on LinkedIn.
Forward Looking StatementsThis press release
contains forward-looking statements, including within the meaning
of the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including statements concerning the development of, and
potential indications for, the Company’s product candidates.
These forward-looking statements are based on management’s
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: we have incurred significant losses, are not currently
profitable and may never become profitable; our projected cash
runway; our need for additional funding; our ability to meet our
debt obligations (including restrictive and operational covenants
and terms of refinanced debt); our ability to cure or
satisfactorily resolve any default arising from our debt
agreements; our limited operating history; our unproven approach to
therapeutic intervention; our ability to address regulatory
questions and the likelihood of regulatory filings and approvals;
the lengthy, expensive, and uncertain process of clinical drug
development, including potential delays in regulatory approval; our
reliance on third parties and collaborators to expand our microbial
library, conduct our clinical trials, manufacture our product
candidates, and develop and commercialize our product candidates,
if approved; our lack of experience in manufacturing, selling,
marketing, and distributing our product candidates; failure to
compete successfully against other drug companies; protection of
our proprietary technology and the confidentiality of our trade
secrets; potential lawsuits for, or claims of, infringement of
third-party intellectual property or challenges to the ownership of
our intellectual property; our patents being found invalid or
unenforceable; risks associated with international operations; our
ability to operate with a reduced workforce, to manage potential
growth and to retain key personnel, particularly following a
significant downsizing; the potential volatility of our common
stock; our management and principal stockholders have the ability
to control or significantly influence our business; costs and
resources of operating as a public company; unfavorable or no
analyst research or reports; the impact of the COVID-19 pandemic on
our operations, including our preclinical studies and clinical
trials, and the continuity of our business; and securities class
action litigation against us.
These and other important factors discussed under the caption
"Risk Factors" in our Quarterly Report on Form 10-Q for the period
ended September 30, 2022, and our other reports filed with the
United States Securities and Exchange Commission, could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, except as
required by law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this press release.
Contacts
Investors:ir@evelobio.com
Media:media@evelobio.com
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Jul 2024 to Jul 2024
Evelo Biosciences (NASDAQ:EVLO)
Historical Stock Chart
From Jul 2023 to Jul 2024